Regeneron’s new biologic boosts small molecule binding

Regeneron’s biologic with deep binding pocket beats conventional antibodies at trapping small molecules

Regeneron has expanded its suite of drug discovery technologies by developing a new type of biologic capable of binding small molecules better than conventional antibodies.

The company has been seeking new technologies -- such as nucleic acid therapies and cell therapies

Read the full 409 word article

User Sign In